EFFECT OF XANTHINE OXIDASE INHIBITORS ON CARDIOVASCULAR OUTCOMES: TRYING TO MAKE SENSE OF THE CONTRADICTORY EVIDENCE

doi:10.4066/biomedicalresearch-C1-002

EFFECT OF XANTHINE OXIDASE INHIBITORS ON CARDIOVASCULAR OUTCOMES: TRYING TO MAKE SENSE OF THE CONTRADICTORY EVIDENCE

Joint Event on 2^nd World Congress on CARDIOLOGY & 39^th Annual Congress on MICROBIOLOGY AND MICROBIAL INFECTION
July 23-24, 2018 | Rome , Italy

Markus Bredemeier

Hospital Nossa Senhora da Conceicao, Brazil

Scientific Tracks Abstracts : Biomed Res

DOI: 10.4066/biomedicalresearch-C1-002

Abstract:

Xanthine oxidase inhibitors (XOI), classified as purine-like (allopurinol and oxypurinol) and non-purine (febuxostat and topiroxostat) XOI, present antioxidant properties by reducing the production of reactive oxygen species derived from purine metabolism. Oxidative stress is an important factor related to endothelial dysfunction and ischemia-reperfusion injury and may be implicated in the pathogenesis of heart failure, hypertension and ischemic heart disease. However, there is contradictory evidence regarding the possible cardiovascular (CV) protective effect exerted by XOI, especially regarding the results of randomized controlled trials. In the present lecture, we discuss in deep the reasons for the disparity in results of different studies from a pharmacodynamic and clinico-epidemiologic point of view, considering the emergence of recent evidence in this field

Biography:

Markus Bredemeier is graduated from Medical School at Federal University of Rio Grande do Sul (1994) and obtained master’s (2003) and PhD (2006) in Medicine: Medical Sciences. Currently, he is practicing at Grupo Hospitalar Conceição (GHC). He worked as Professor of Clinical Pharmacology at the Faculty of Dentistry, Lutheran University of Brazil, from 1997 to 2005. He has 55 scientific articles published in medical journals, of which 42 are indexed in PubMed. He founded and supervises the residency program in Rheumatology of the GHC. In October 2013, he received the award Luiz Felipe Cunha Mattos (first place) for the work low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. The updated version of this study was presented orally at the EULAR 2015 Congress. In 2017, presented orally the study effect of xanthine oxidase inhibitors on the incidence of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials at the EULAR Congress Madrid.

E-mail: markbred@terra.com.br

PDF HTML